

[図1]



SHED-T
SHED-C
個体数倍加回数(回)
300
250
200
150
100
50
0
0
200
400
600
800
1,000
時間(日)

[図2]



(A)正常細胞
PD20
27%
(B)正常細胞
PD30
15%
(C)不死化幹細胞
PD20
46%
(D)不死化幹細胞
PD40
41%
相対的細胞数
STRO-1の発現
0
20
40
60
80
100
120
10^0
10^1
10^2
10^3
10^4

[図3]


(A)




(B)



[図4]




[図5]




[図6]


(A)



(B)




[図7]




[図8]

(A)




(B)




[図9]


(A)



(B)




[図10]




[図11]


嗅球を介した幹細胞由来の培養上清の経鼻投与




[図12]



[図13]




[図14]




[図15]


(A)



(B)



[図16]




[図17]


(A)




(B)




[図18]


(A)
MMS
長谷川式
インデックス値
18
15
10
5
0
1
2
3
4
5
6
7
8
9
10
11
12
投与期間(月)


(B)
MMS
長谷川式
インデックス値
35
30
25
20
15
10
5
0
1
2
3
4
5
6
7
8
9
10
11
12
投与期間(月)

[図19]

(A)



(B)

